Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copaxone 40 mg vs 20 mg in RRMS
NCT00202982Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2003
- Primary completion
- Sep 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Total number of T1 Gd-enhancing lesions at 9 months. Started Aug 2003; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00202982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202982.